Company Overview - Echo IQ is an AI and Medical Technology company based in Sydney, Australia, focused on improving decision-making in Cardiology through AI-driven technology and proprietary software [4]. Recent Developments - The CEO of Echo IQ, Dustin Haines, will present at the Life Sciences Virtual Investor Forum on December 11, 2025 [1][2]. - EchoSolv AS, an FDA-approved solution, has seen significant commercial traction in the U.S., with a 153% increase in echocardiograms processed from July to September 2025 [6]. - There was a 58% uplift in echocardiogram processing from September to October 2025 [6]. - The company entered into a reseller agreement with SARC MedIQ, expanding the use of EchoSolv AS through a network of hospitals and cardiology practices in the U.S. [6]. Clinical Results - Preliminary top-line clinical results from the EchoSolv HF validation study show a sensitivity of 99.5% and specificity of 91.0% in identifying patients with and without Heart Failure, respectively [6]. - The company plans to submit for FDA clearance of EchoSolv HF via the 510(k) regulatory pathway in December 2025, anticipating clearance in the first half of calendar year 2026 [6]. Market Context - Heart failure and aortic stenosis are significant health challenges in the U.S., driving over US$65 billion in annual healthcare costs [6].

Core Insights - Echo IQ has announced significant findings from two studies presented at the AHA Scientific Sessions 2025, highlighting gaps in the current standard-of-care for diagnosing and monitoring severe aortic stenosis (AS) and the potential of EchoSolv AS to improve patient outcomes [1][2]. Company Overview - Echo IQ is an AI and medical technology company focused on enhancing decision-making in cardiology through advanced analytics and AI [14]. - The company aims to transform severe AS care, particularly addressing the shortcomings of the "watchful waiting" strategy for moderate-to-severe AS cases [2][12]. Study Findings - A study involving over 1.2 million patients revealed that the traditional "watchful waiting" approach is inadequate, leading to significant health risks [2][12]. - EchoSolv AS demonstrated superior accuracy in identifying severe AS phenotypes compared to cardiologists, especially in women and low-gradient cases [6][11]. - The male-to-female diagnosis ratio improved from 2.2:1 to 1.1:1 with EchoSolv's implementation, indicating enhanced gender equity in diagnosis [6]. Clinical Implications - The studies underscore the urgent need for improved monitoring and diagnosis of severe AS, as only 36% of women and 45% of men with moderate-to-severe AS received timely intervention [12]. - EchoSolv AS is positioned to facilitate more precise identification of high-risk AS patients, supporting timely clinical decisions regarding interventions [11]. Research Methodology - The studies were conducted by researchers from the University of Notre Dame Australia, utilizing data from the National Echo Database of Australia (NEDA) [9][10]. - The first study compared traditional cardiologist reporting with EchoSolv, analyzing 30,878 echocardiograms [3][5]. - The second study analyzed echocardiography data from 1.18 million subjects, linking health service delivery to patient outcomes [9].